Skip to content

A Pilot Randomized Controlled Trial for Feasibility of Administering an AR Game to Postoperative Pediatric Cancer Patients

A Pilot Randomized Controlled Trial to Determine the Feasibility of Administering an auGmented reAlity gaMe to pediatrIc caNcer Patients underGoing Surgery (A GAMING Study)

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04674150
Acronym
GAMING
Enrollment
20
Registered
2020-12-19
Start date
2021-01-13
Completion date
2021-11-30
Last updated
2021-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pediatric Cancer, Surgery

Brief summary

This is a pilot study to evaluate the feasibility of SpellBound's AR (augmented reality)-enabled scavenger hunt use among 20 pediatric cancer patients undergoing surgery.

Interventions

DEVICEARISE with AR

An augmented reality game for mobile devices with AR experiences enabled

DEVICEARISE without AR

An augmented reality game for mobile devices with AR experiences disabled as an control

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
M.D. Anderson Cancer Center
CollaboratorOTHER
Baylor College of Medicine
CollaboratorOTHER
ALTality, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years
Healthy volunteers
No

Inclusion criteria

1. Ages 3-18 2. English speaking parents/legal guardians and patients 3. Undergoing major surgery for cancer requiring postoperative hospitalization defined as ≥2 hours of duration of surgery and requiring postoperative hospital admission of at least one night 4. Expected to be prescribed postoperative inpatient opioids 5. Have never taken opioids or have had no daily opioid use within the last 30 days 6. Sufficient cognitive capacity to comprehend and interact with the game. This is defined as ability to utilize mobile technology (use iPad with or without assistance) and activate and respond to AR experiences within the app as determined by the clinician. 7. Both child and a legal guardian are willing and able to provide informed consent.

Exclusion criteria

1. History of documented peripheral neuropathy secondary to cancer treatment 2. Inability to demonstrate an understanding of the game from English instructions 3. Have previous played the ARISETM digital scavenger hunt game 4. Any additional concerns based on the study physicians' assessments

Design outcomes

Primary

MeasureTime frameDescription
Percentage of patients who receive the AR game who are able to initiate the game and activate any targets with 1% error rateThe patient's postoperative inpatient hospital stay, average 7 daysSuccess defined as at least 80% of patients who receive the AR game being able to initiate the game and activate any targets with 1% error rate

Secondary

MeasureTime frameDescription
Inpatient opioid useThe patient's postoperative inpatient hospital stay, average 7 daysThe average daily inpatient MEDD (morphine equivalent dose) will be calculated from the electronic medical record as previously used in pediatric cancer surgical patients by the investigator
Outpatient opioid useThe patient's postoperative inpatient hospital stay, average 7 daysWe will record whether the patient has any active opioid prescription 90-days (±10 Days) after surgery. This data will be confirmed by direct contact to patients' caregivers or via pharmacy registries on filled prescriptions.
Average daily inpatient pain scoreThe patient's postoperative inpatient hospital stay, average 7 daysAge-appropriate pain-intensity scores will be determined using Visual and Colored Analogue Scales (VAS). This is a 10-point colored scaled validated for measuring pain intensity in pediatric populations and will be assessed twice daily at 9AM and 5PM.
Number of opioid requests (rescue analgesia)The patient's postoperative inpatient hospital stay, average 7 daysWe will record the total number of times opioids were required by patients to nurses and the patient-controlled analgesia infusion pumps during the inpatient period as recorded in the electronic medical record.
Quality of life assessmentThe patient's postoperative inpatient hospital stay, average 7 daysAge-appropriate Pediatric Quality of Life Inventory (PedsQL) paper surveys will be administered to the patient (self-report) or guardian (proxy) when patients reach discharge-ready status.
Discharge-ready statusThe patient's postoperative inpatient hospital stay, average 7 daysThe number of days to discharge-ready status will be determined by the study physicians. This status will be assessed twice daily at 9AM and 5PM.
Patient experienceThe patient's postoperative inpatient hospital stay, average 7 daysIn the patients who receive the AR game, responses to an electronic survey on the patient's experience designed by the MDACC Child Life team will be recorded when patients reach discharge-ready status.
Outpatient pain scores90 days after the patient is discharged from the hospitalWe will record average pain intensity experience by the patient during the 90-day (±10 Days) post surgery period. This data will be confirmed by direct contact to patient's guardian or as recorded in the electronic medical record during the patient's follow-up clinic visit
Outpatient quality of life90 days after the patient is discharged from the hospitalAge-appropriate Pediatric Quality of Life Inventory (PedsQL) surveys will be administered to the patient (self-report) or guardian (proxy) by phone.
Ambulation/ out of bed movementThe patient's postoperative inpatient hospital stay, average 7 daysDistance (meters) achieved out of bed (ambulatory or non-ambulatory/wheelchair) during their inpatient stay while interacting with the app will be calculated by hand, based on how many times patient activated specific targets.

Other

MeasureTime frameDescription
Adverse eventsThrough study completion, average 4-month time periodAny adverse events clinically determined to be related to the use of AR (i.e., falls) will be recorded

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026